Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubral pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract: A connection structure for a superconducting layer according to an embodiment includes a first superconducting layer, a second superconducting layer, and a connection layer between the first superconducting layer and the second superconducting layer, the connection layer including crystal particles containing a rare earth element, barium, copper, and oxygen, the crystal particles having a major diameter distribution including a trimodal distribution. The trimodal distribution has first, second, and third distributions in which major diameter become small in this order. The aspect ratios of the crystal particles included in the first distribution and the second distribution include a bimodal distribution. The median value of the major diameters of the crystal particles included in the distribution on a higher aspect ratio side in the bimodal distribution is greater than the median value of the major diameters of the crystal particles included in the distribution on a lower aspect ratio side.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: A connection structure of a superconducting layer according to an embodiment includes a first superconducting layer, a second superconducting layer, and a connection layer provided between the first superconducting layer and the second superconducting layer and including a first substance containing a rare earth element, barium, copper, and oxygen and a second substance containing a metal element, in which a first region per unit area at a first interface between the first superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the first superconducting layer are in contact with each other, and a second region per unit area at a second interface between the second superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the second superconducting layer are in contact with each other.

Abstract: A superconducting layer joint structure of embodiments includes: a first superconducting layer; a second superconducting layer; and a joint layer provided between the first superconducting layer and the second superconducting layer and containing a plurality of crystal particles containing a rare earth element (RE), barium (Ba), copper (Cu), and oxygen (O). The plurality of crystal particles includes at least one first particle. The at least one first particle has a first inner region and a first outer region. The first inner region is disposed inside the first superconducting layer. The first outer region is disposed outside the first superconducting layer.

Abstract: A connection structure of a superconducting layer of an embodiment incudes a first superconducting member including a first superconducting layer, and extends in a first direction, a second superconducting member including a second superconducting layer facing the first superconducting layer, and extends in the first direction, the second superconducting member having a first region, a second region, and a third region which is separated in the second direction from the second region, and a connection layer that contains a rare earth element (RE), barium (Ba), copper (Cu), and oxygen (O), and connects the first superconducting layer and the second superconducting layer. The first superconducting layer is present in a third direction between the second region and the third region, the third direction being perpendicular to the first direction and perpendicular to the second direction.

Abstract: A connection structure for a superconducting layer according to an embodiment includes a first superconducting layer, a second superconducting layer, and a connection layer between the first superconducting layer and the second superconducting layer, the connection layer including crystal particles containing a rare earth element, barium, copper, and oxygen, the crystal particles having a major diameter distribution including a trimodal distribution. The trimodal distribution has first, second, and third distributions in which major diameter become small in this order. The aspect ratios of the crystal particles included in the first distribution and the second distribution include a bimodal distribution. The median value of the major diameters of the crystal particles included in the distribution on a higher aspect ratio side in the bimodal distribution is greater than the median value of the major diameters of the crystal particles included in the distribution on a lower aspect ratio side.

Abstract: A structure according to the embodiment includes a first crystal grain, a second crystal grain, and a first region. The first crystal grain includes silicon nitride. The second crystal grain includes a first element selected from a first group consisting of scandium, yttrium, lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, aluminum, chromium, zirconium, magnesium, zinc, titanium, gallium, beryllium, calcium, strontium, barium, hafnium, vanadium, niobium, tantalum, tungsten, iron, cobalt, nickel, and copper, and oxygen. The first region includes an oxide of the first element.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: A connection structure of a superconducting layer according to an embodiment includes a first superconducting layer, a second superconducting layer, and a connection layer provided between the first superconducting layer and the second superconducting layer and including a first substance containing a rare earth element, barium, copper, and oxygen and a second substance containing a metal element, in which a first region per unit area at a first interface between the first superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the first superconducting layer are in contact with each other, and a second region per unit area at a second interface between the second superconducting layer and the connection layer is 1% or more and 50% or less where the second substance and the second superconducting layer are in contact with each other.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.